Oremek G M, Sapoutzis N, Kramer W, Bickeböller R, Jonas D
Klinikum der Johann-Wolfgang Goethe-Universität Frankfurt, Zentrallabor-Zentrum der Inneren Medizin, Theodor-Stern-Kai 7, D-60590 Frankfurt/Main, Germany.
Anticancer Res. 2000 Nov-Dec;20(6D):5095-8.
Pyruvate kinase is one of the glycolytic key enzymes. It exists in various isoforms which are expressed in different cell types. One of these isoforms, the type Tu M2-PK, is strongly overexpressed by tumor cells and released into body fluids. The concentration of Tu M2-PK in body fluids can be quantitatively determined by a commercially available enzyme-linked immunosorbent assay (ELISA)-kit. The Tu M2-PK concentration was measured in EDTA-plasma of 116 patients with renal carcinoma and 42 patients suffering from nephritis, by using this kit. The ranges of the Tu M2-PK-concentrations of the two groups did not overlap, indicating a highly significant discrimination of renal carcinoma and benign renal diseases. Furthermore, the Tu M2-PK concentration in EDTA-plasma correlated strongly with the Robson tumor stage of the 116 patients. The present results indicated that the Tu M2-PK might be the first tumor marker, which could be an excellent complementation of the diagnostic program for renal carcinoma.
丙酮酸激酶是糖酵解关键酶之一。它以多种同工型存在，在不同细胞类型中表达。其中一种同工型，即M2-PK Tu型，在肿瘤细胞中强烈过表达并释放到体液中。体液中Tu M2-PK的浓度可通过市售的酶联免疫吸附测定（ELISA）试剂盒进行定量测定。使用该试剂盒测定了116例肾癌患者和42例肾炎患者的EDTA血浆中Tu M2-PK的浓度。两组的Tu M2-PK浓度范围没有重叠，表明肾癌与良性肾脏疾病有高度显著的区分。此外，116例患者的EDTA血浆中Tu M2-PK浓度与罗布森肿瘤分期密切相关。目前的结果表明，Tu M2-PK可能是首个肿瘤标志物，可作为肾癌诊断方案的极佳补充。
